Sera Prognostics, Inc. Stock Price, News & Analysis

Sera Prognostics Inc. (NASDAQ: SERA) announced the appointment of Sandra A. J. Lawrence to its Board of Directors. Ms. Lawrence brings extensive leadership experience and insights from her roles in public and private boards, as well as her tenure as CFO at Children’s Mercy Hospital. The company aims to leverage her expertise to enhance maternal and neonatal health and drive long-term revenue growth. Sera Prognostics specializes in innovative pregnancy biomarker solutions, particularly its PreTRM® test, which aims to predict preterm birth risks.

Sera Prognostics Inc. (Nasdaq: SERA) reported a significant revenue increase for Q3 2021, achieving $23,000 compared to $5,000 in Q3 2020. Operating expenses rose to $9.5 million from $4.6 million, primarily due to expanded sales operations and public company costs. R&D spending increased to $2.7 million, reflecting heightened clinical study efforts. The company faced a net loss of $9.9 million, up from $5.1 million year-over-year. Sera continues to see early payer revenues for its PreTRM® test, emphasizing its commitment to improving maternal and neonatal health.

Sera Prognostics, Inc. (NASDAQ: SERA) announced the appointment of Zhenya Lindgardt to its Board of Directors, effective immediately. Lindgardt, with extensive experience in healthcare and technology, aims to enhance the company's mission to improve maternal and neonatal health. Currently the CEO of The Commons Project Foundation, she has also held significant positions at Uber Technologies and The Boston Consulting Group. CEO Gregory C. Critchfield expressed enthusiasm about Lindgardt’s contributions towards innovative solutions for pregnancy-related challenges.

Sera Prognostics (NASDAQ: SERA) has appointed Woodrow Myers, M.D., M.B.A., as an advisor for public and political affairs. Dr. Myers will spearhead initiatives addressing health equity and disparities during pregnancy, a significant focus for the company. Gregory C. Critchfield, CEO, emphasized Dr. Myers' leadership experience in healthcare management and quality initiatives. Sera Prognostics aims to enhance maternal and neonatal health through innovative diagnostic tests like the PreTRM®, which predicts preterm birth risk, thereby enabling timely interventions.

Sera Prognostics (NASDAQ: SERA) announced the publication of a rigorous validation for its PreTRM® test, identifying a clinical decision point at a 15% risk for spontaneous preterm birth (sPTB). The findings, from the PAPR and TREETOP studies involving over 10,000 subjects, indicate that patients at or above this threshold face significantly higher risks, including severe neonatal morbidity. This validation supports the clinical utility of the PreTRM® test in proactive maternal care, potentially improving pregnancy outcomes and reducing healthcare costs.

Sera Prognostics (NASDAQ: SERA) announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families to support families affected by preterm birth. This collaboration aims to address healthcare disparities, particularly among African Americans, who are 50% more likely to experience premature delivery. The initiative includes distributing a children's book, Will Our Egg Hatch Early?, focusing on preterm birth risks. Sera's PreTRM^® test offers early risk prediction for preterm births, enhancing proactive prenatal care.

Sera Prognostics (NASDAQ: SERA) will report its third quarter 2021 financial results on November 9, 2021, after market close. This announcement includes a conference call at 5:00 p.m. ET for discussing operational highlights and financial results. Sera Prognostics specializes in improving maternal and neonatal health through innovative pregnancy biomarker information, notably its PreTRM® test, which predicts preterm birth risk. The company aims to enhance healthcare while reducing costs through early intervention.

Sera Prognostics, Inc. (NASDAQ: SERA), known as The Pregnancy Company™, has appointed Dr. Paul Kearney as Chief Data Officer, effective October 1, 2021. Dr. Kearney will leverage his extensive experience in data science and bioinformatics to enhance Sera's research and commercial activities related to pregnancy health. He has co-founded successful biotech firms and has a strong background in clinical research and product development. The company remains focused on innovative prenatal health diagnostics, exemplified by its PreTRM® test, which predicts preterm birth risk through blood biomarkers.

Sera Prognostics, Inc. (Nasdaq: SERA) has been added to the Russell 2000 Index effective September 20, 2021, enhancing its visibility within the investment community. This milestone follows the company’s transition to a public entity in July 2021. The company focuses on improving maternal and neonatal health through innovative biomarker testing, particularly its PreTRM test, which predicts preterm birth risk. Sera aims to expand revenue and shareholder value through increased awareness and adoption of its services.